Form 4: Axsome Therapeutics CFO Nick Pizzie Executes Option Exercise and Stock Sale Under 10b5-1 Plan
SEC Form 4
Axsome Therapeutics' CFO, Nick Pizzie, exercised stock options and sold shares under a pre-approved 10b5-1 trading plan, completing the plan's transactions.
Summary
- Nick Pizzie, the CFO of Axsome Therapeutics, exercised stock options to purchase 12,000 shares on February 13, 2025, at a price of $3.50 per share.
- He then sold these 12,000 shares on the same day at a weighted average price of $129.86 per share, with prices ranging from $128.50 to $131.64.
- On February 14, 2025, Pizzie exercised options for another 3,000 shares at $3.50 per share and sold them at a weighted average price of $131.07 per share, with prices ranging from $130.06 to $131.72.
- These transactions were executed under a pre-approved 10b5-1 trading plan, which has now been completed.
- Following these transactions, Pizzie directly owns 42,187 shares of Axsome Therapeutics common stock.
- He also indirectly owns 488 shares as custodian for his children's UTMA accounts.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing plan. There's no indication of positive or negative implications for the company's performance.
Positives
- The transactions were executed under a pre-approved 10b5-1 trading plan, indicating compliance with insider trading regulations.
Industry Context
Transactions of this nature are common among corporate executives and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Comparison to Industry Standards
- Executive stock option exercises and sales are a standard part of executive compensation across the pharmaceutical industry.
- Companies like Eli Lilly, Pfizer, and Johnson & Johnson also see similar transactions from their executives regularly.
- The use of 10b5-1 plans is a common practice to ensure compliance with SEC regulations, mirroring practices at companies like Amgen and Biogen.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
Key Dates
| Date | Description |
|---|---|
| 05/16/2019 | Original grant date of stock options that were exercised. |
| 05/16/2028 | Expiration date of the stock options. |
| 02/13/2025 | Date of first transaction: exercise of options for 12,000 shares and subsequent sale. |
| 02/14/2025 | Date of second transaction: exercise of options for 3,000 shares and subsequent sale. |
Keywords
Axsome Therapeutics, Nick Pizzie, CFO, stock options, 10b5-1 plan, insider trading, AXSM, UTMA accounts, stock sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.